Sample Size estimation for Replicate Cross over studies FDA or EMA criteria [Power / Sample Size]

posted by Lara – Mexico, 2016-02-10 01:46 (3365 d 10:54 ago) – Posting: # 15966
Views: 26,276

Hi,

I have review the paper:

Someswara Roa. K et al. "Sample Size Estimation for Highly variable drugs using reference scaled average bioequivalence criteria". International Journal of Recent Scientific Research Vol. 6 Issue 7, pp.5040-5045, July, 2015.

They are determined the optimal sample size for reference scaled average bioequivalence under criteria of FDA and EMA. The paper has several tables with the sample size according with FDA and EMA criteria for the designs partial replicate 2x2x3 and full replicate 2x2x4 and use the BE limit. However, they are using the estimation of the sample size for a simple crossover. I am not sure that this is correct starting with df=2*n-2 and I do not know when they are using the characteristics of the designs. Can somebody help me with that?

Thanks

Lara


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
85 visitors (0 registered, 85 guests [including 1 identified bots]).
Forum time: 13:41 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5